RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership Transaction represents RepliCel’s entrance into the U.S. marketInvestment terms minimize dilution and puts RepliCel on-track for US FDA marketing approvals of the RepliCel Dermal Injector Product Line...

RepliCel Q3 2020 Management Update VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) -- RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation...

Canada and Japan Leading Innovation in Regenerative Medicine; Two Nations, Different Strategies, One Goal: Addressing Incurable Medical Conditions VANCOUVER, British Columbia, March 10, 2015 (GLOBE NEWSWIRE) -- Canada and Japan are taking distinctly different but complementary paths in the development of a regenerative medicine industry within...

Cutting-Edge Advancements: New Technology Puts Your Own Cells to Work to Repair and Rejuvenate Your Body VANCOUVER, B.C., Sept. 9, 2014 (GLOBE NEWSWIRE) -- There is enormous interest in the worlds of medicine and esthetics in the promise of regenerative medicine. From cellular replacement techniques for...